U.S. Markets close in 6 hrs 1 min

Lonza Group Ltd (LONN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
652.80-11.00 (-1.66%)
As of 03:43PM CET. Market open.

Lonza Group Ltd

Muenchensteinerstrasse 38
Basel 4002
41 61 316 81 11

IndustryDiagnostics & Research
Full Time Employees14,405

Key Executives

NameTitlePayExercisedYear Born
Dr. Pierre-Alain Ruffieux Ph.D.Chief Exec. Officer1.11MN/A1969
Mr. Philippe DeeckeChief Financial OfficerN/AN/AN/A
Mr. Dirk OehlersVP of Investor RelationsN/AN/AN/A
Victoria MorganHead of External CommunicationsN/AN/AN/A
Ms. Jennifer ClancySr. Director of Global MarketingN/AN/AN/A
Ms. Caroline BarthChief HR OfficerN/AN/A1972
Ms. Constance WardHead of External CommunicationsN/AN/AN/A
Mr. Stefan StoffelChief Operating Officer of Pharma & Biotech SegmentN/AN/A1966
Dr. Sanna FowlerHead of External CommunicationsN/AN/AN/A
Dr. Matthias HofmannHead of Corp. Environment, Health, Safety & SustainabilityN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.


Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications. It serves pharmaceutical companies, biotechnology firms, and medical research and testing organizations, as well as consumer health and nutrition companies. The Specialty Ingredients segment engages in the microbial control solutions and specialty chemical services businesses. Its Microbial control solutions business has offerings in professional hygiene, and home and personal care markets; and offerings in paints and coating, wood protection, material protection, and crop protection. This segment also offers specialty chemicals in electronics, aerospace, food and feed ingredients, agrochemicals, and diversified specialty chemicals markets. The company has a strategic collaboration agreement with Moderna, Inc. to manufacture a potential COVID-19 vaccine, mRNA-1273; and CellPoint B.V to deliver CAR-T cells to patients at point-of-care. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

Corporate Governance

Lonza Group Ltd’s ISS Governance QualityScore as of September 26, 2021 is 1. The pillar scores are Audit: 4; Board: 1; Shareholder Rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.